ATE325621T1 - Il-12 als adjuvanz für bordetella pertussis impfstoffe - Google Patents

Il-12 als adjuvanz für bordetella pertussis impfstoffe

Info

Publication number
ATE325621T1
ATE325621T1 AT97932137T AT97932137T ATE325621T1 AT E325621 T1 ATE325621 T1 AT E325621T1 AT 97932137 T AT97932137 T AT 97932137T AT 97932137 T AT97932137 T AT 97932137T AT E325621 T1 ATE325621 T1 AT E325621T1
Authority
AT
Austria
Prior art keywords
adjuvance
bordetella pertussis
pertussis vaccines
vaccines
bordetella
Prior art date
Application number
AT97932137T
Other languages
English (en)
Inventor
Kingston H G Mills
Bernard P Mahon
Mark S Ryan
Fiona Griffin
Original Assignee
Nat Univ Ireland Maynooth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Ireland Maynooth filed Critical Nat Univ Ireland Maynooth
Application granted granted Critical
Publication of ATE325621T1 publication Critical patent/ATE325621T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97932137T 1996-05-31 1997-05-30 Il-12 als adjuvanz für bordetella pertussis impfstoffe ATE325621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1587196P 1996-05-31 1996-05-31
US82986597A 1997-03-31 1997-03-31

Publications (1)

Publication Number Publication Date
ATE325621T1 true ATE325621T1 (de) 2006-06-15

Family

ID=26687907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97932137T ATE325621T1 (de) 1996-05-31 1997-05-30 Il-12 als adjuvanz für bordetella pertussis impfstoffe

Country Status (10)

Country Link
US (5) US6929794B1 (de)
EP (2) EP1649868A1 (de)
JP (2) JP3737519B2 (de)
AT (1) ATE325621T1 (de)
AU (1) AU724743B2 (de)
DE (1) DE69735856T2 (de)
DK (1) DK1015026T3 (de)
ES (1) ES2262181T3 (de)
PT (1) PT1015026E (de)
WO (1) WO1997045139A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325621T1 (de) * 1996-05-31 2006-06-15 Nat Univ Ireland Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe
WO1999040936A2 (en) * 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
CA2322337A1 (en) * 1998-03-05 1999-09-10 The Medical College Of Ohio Enhancement of immunity by intranasal inoculation of il-12
IL146382A0 (en) 1999-05-13 2002-07-25 American Cyanamid Co Adjuvant combination formulations
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
AU7003101A (en) * 2000-06-22 2002-01-02 American Cyanamid Co Qs-21 and il-12 as an adjuvant combination
IL155690A0 (en) * 2000-11-10 2003-11-23 Wyeth Corp Adjuvant combination formulations
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
WO2012104821A1 (en) * 2011-02-04 2012-08-09 Pfizer Inc. Immunogenic bordetella bronchiseptica compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
US4705686A (en) * 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
JPH01193231A (ja) * 1988-01-27 1989-08-03 Takeda Chem Ind Ltd 抗腫瘍剤
CA2441636A1 (en) 1988-11-10 1990-05-10 The Wistar Institute Of Anatomy And Biology Natural killer stimulatory factor
US5162223A (en) * 1989-02-17 1992-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
AU648509B2 (en) * 1989-07-14 1994-04-28 Wyeth Holdings Corporation Stable vaccine compositions containing interleukins
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
WO1994001139A1 (en) 1992-07-13 1994-01-20 Baylor College Of Medicine Targeting somatic gene therapy to joints
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
ATE229978T1 (de) 1994-07-01 2003-01-15 Chiron Corp Helicobacter proteine und impstoffe
AU3735095A (en) 1994-09-30 1996-04-26 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
ES2257744T3 (es) * 1994-10-05 2006-08-01 Vanderbilt University Interleuquina-12 como adyuvante para vacunas contra paramyxoviridae.
WO1997000321A1 (en) 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
ATE325621T1 (de) * 1996-05-31 2006-06-15 Nat Univ Ireland Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe

Also Published As

Publication number Publication date
JP2001527516A (ja) 2001-12-25
DE69735856D1 (de) 2006-06-14
WO1997045139A2 (en) 1997-12-04
DK1015026T3 (da) 2006-09-11
DE69735856T2 (de) 2006-11-16
US20060257419A1 (en) 2006-11-16
AU3567097A (en) 1998-01-05
WO1997045139A3 (en) 1998-02-12
US20050158276A1 (en) 2005-07-21
US6929794B1 (en) 2005-08-16
US20060263380A1 (en) 2006-11-23
PT1015026E (pt) 2006-08-31
EP1015026A2 (de) 2000-07-05
JP3737519B2 (ja) 2006-01-18
EP1649868A1 (de) 2006-04-26
JP2005112865A (ja) 2005-04-28
US20060263379A1 (en) 2006-11-23
EP1015026B1 (de) 2006-05-10
ES2262181T3 (es) 2006-11-16
AU724743B2 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
ATE325621T1 (de) Il-12 als adjuvanz für bordetella pertussis impfstoffe
GB9713156D0 (en) Vaccines
NL300402I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
DE69930166D1 (de) Verfahren und zusammensetzungen für impfung mit dem pseudomonas aeruginosa v-antigen
IT1272190B (it) Composizione indurente e metodo per l'impregnazione di legno.
FI893512L (fi) Bordetella pertussis-vaccin.
ITAN940011A0 (it) Dispositivo di arresto ammortizzato per serrande o tapparelle
ES2136443T3 (es) Limpieza in situ.
ITAN940006V0 (it) Dispositivo di arresto ammortizzato per serrande o tapparelle
ITMI910371V0 (it) Canaletta ecologica per la risagomatura di fossi, o similari, e per la correzione della pendenza di questi ultimi
DE69128095D1 (de) Azelluläre impfstoffe
IT9047612A0 (it) Dispositivo di ancoraggio di protesi dentarie e suo metodo di installazione.
IT7953755U1 (it) Apparato depolveratore per depurare l'aria ambiente da polvere e da trucioli di legno, di metallo e simili provenienti da macchine operatrici.
IT9020880A0 (it) Dispositivo e metodo per la proiezione di diapositive.
HUP9902885A1 (hu) Maláriaellenes vakcinakészítmények
IT9004711U1 (it) Apparecchiatura per la posa di cordoli stradali e simili.
IT9003315A1 (it) Apparecchiatura per la posa di cordoli stradali e simili.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1015026

Country of ref document: EP

REN Ceased due to non-payment of the annual fee